Edap Tms (EDAP) to Release Quarterly Earnings on Thursday

Edap Tms (NASDAQ:EDAP) is expected to issue its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Edap Tms to post earnings of ($0.22) per share and revenue of $19.2890 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.

Edap Tms (NASDAQ:EDAP) last posted its quarterly earnings data on Wednesday, March 25th. The medical equipment provider reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.09). The business had revenue of $22.22 million during the quarter, compared to analyst estimates of $21.28 million. Edap Tms had a negative net margin of 41.24% and a negative return on equity of 100.07%. On average, analysts expect Edap Tms to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Edap Tms Stock Performance

NASDAQ:EDAP traded up $0.09 during mid-day trading on Tuesday, reaching $3.43. The stock had a trading volume of 13,858 shares, compared to its average volume of 56,545. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.19 and a current ratio of 1.54. Edap Tms has a twelve month low of $1.21 and a twelve month high of $5.05. The firm has a market capitalization of $128.56 million, a price-to-earnings ratio of -4.45 and a beta of -0.10. The business has a 50 day simple moving average of $3.77 and a 200 day simple moving average of $3.34.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on EDAP. Wall Street Zen cut Edap Tms from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. HC Wainwright cut their price objective on Edap Tms from $14.00 to $10.00 and set a “buy” rating on the stock in a research report on Thursday, April 9th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $6.00.

Hedge Funds Weigh In On Edap Tms

An institutional investor recently raised its position in Edap Tms stock. Rock Springs Capital Management LP boosted its position in Edap Tms S.A. (NASDAQ:EDAP) by 1.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,286,500 shares of the medical equipment provider’s stock after purchasing an additional 16,500 shares during the period. Rock Springs Capital Management LP owned approximately 3.44% of Edap Tms worth $4,233,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 62.74% of the company’s stock.

About Edap Tms

Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.